17 April 2025

Genetic Sequencing in Rheumatology

Genetic sequencing as a research and diagnostic tool has expanded in medicine and rheumatology. An interesting review in Arthritis and Rheumatology suggests that despite currently modest use, there will be an expanded role for genetic sequencing in the field of rheumatology.

17 April 2025

The Increasing Cost of First-Line Biologics for Plaque Psoriasis

A national commercial claims analysis of first-line use of biologics in biologic−naive plaque psoriasis patients found a near doubling of net treatment costs from 2007 to 2021 ($21 236 to $47 125). Despite the increasing costs, the 2021 average cost could have been 44% lower if the lowest-cost drug in the same mechanistic class were chosen.

Enzyme Porcupine inhibition of Wnt signaling is a promising treatment forsclerosteosis - rare Dz caused by SOST mutation

Tweet Author

RheumNow

Tweet Content

Enzyme Porcupine inhibition of Wnt signaling is a promising treatment forsclerosteosis - rare Dz caused by SOST mutations & loss of functional sclerostin. Results in high bone mass & skeletal overgrowth (Sxs of facial paralysis, hearing loss, incr intracranial pressure https://t.co/9DYO82quiC

JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF

Tweet Author

RheumNow

Tweet Content

JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF

Links

What Is Scleroderma? https://buff.ly/5gqGL6j

Ultrasound lesions of dactylitis associ w/short-term development of PsA. Study of 64 PsO +arthralgia pts. IUS PD synovi

Tweet Author

RheumNow

Tweet Content

Ultrasound lesions of dactylitis associ w/short-term development of PsA. Study of 64 PsO +arthralgia pts. IUS PD synovitis & B mode enthesitis predicted PsA Dx (p < .001) w/ an accuracy of 89.1 %, a sensitivity of 86.7 % and a specificity of 89.8 %. https://t.co/Ij6oYP1TuK https://t.co/55sO4uFXNI

Links

https://buff.ly/GjABLv0

Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep

Tweet Author

RheumNow

Tweet Content

Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep 80mg vs PBO at wk 16 (52% vs 13%; p=0.0006) w/ 40mg=48%. Other arthritis, psoriasis, enthesitis, dactylitis, QOL outcomes also improved.https://t.co/CQn9EVjr9g https://t.co/vVnTo2FPV6

Links

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a … https://buff.ly/ze7XbtM

AutoAbs & protein signatures evolve as pts go from Preclinical to established RA. Pts vs controls distinguished w/in

Tweet Author

RheumNow

Tweet Content

AutoAbs & protein signatures evolve as pts go from Preclinical to established RA. Pts vs controls distinguished w/in 5 yrs of Dx best by iCCP3, RFIgA, RFIgM; and 104 proteins differentially expressed & gene analyses showed 21 pathways enriched ≤5 years of Dx. https://t.co/u8abvqNtnX

Daily purposeful walking assoc w/ lower risk of Knee OA (KOA). UK Biobank study of 89,969 persons, F/U 6.8 yrs - 2711 de

Tweet Author

RheumNow

Tweet Content

Daily purposeful walking assoc w/ lower risk of Knee OA (KOA). UK Biobank study of 89,969 persons, F/U 6.8 yrs - 2711 developed KOA. HRs for incident KOA were 0.84 (0.76-0.92), 0.81 (0.71-0.90), and 0.74 (0.64-0.85) if walking ~5000, ~7000, & ≥8000 steps/d, respectively https://t.co/St9QLuOy9R

Phase 3 trial shows inebilizumab reduces flares in IgG4-related disease (10% vs 60% in placebo; HR 0.13, p<0.001) and

Tweet Author

DrNatashaSalman

Tweet Content

Phase 3 trial shows inebilizumab reduces flares in IgG4-related disease (10% vs 60% in placebo; HR 0.13, p<0.001) and boosts remission rates without background immunosuppressants. CD19+ B-cell depletion shows promise as a new treatment. #Rheum @RheumNow https://t.co/7iSyPfnMV0 https://t.co/M51b0dipMs

Links

Inebilizumab for Treatment of IgG4-Related Disease | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2409712

https://x.com/DrNatashaSalman/status/1911917391921221767/photo/1

✅ T2T in #Lupus 👀 ⬇️⬇️ 📥 LINK https://t.co/F8w8qRZdsS #NosVemosEnPANLAR2025 https://t.co/JNx1wdwMb4

Tweet Author

Lupusreference

Tweet Content

✅ T2T in #Lupus 👀 ⬇️⬇️ 📥 LINK https://t.co/F8w8qRZdsS #NosVemosEnPANLAR2025 https://t.co/JNx1wdwMb4

Links

Framework for implementing treat-to-target in systemic lupus erythematosus rout… https://authors.elsevier.com/a/1kdub5alwYF%7EsD

https://x.com/Lupusreference/status/1905138987330568416/photo/1

Topics

Genetic Sequencing in Rheumatology

Enzyme Porcupine inhibition of Wnt signaling is a promising treatment forsclerosteosis - rare Dz caused by SOST mutation

JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF

Ultrasound lesions of dactylitis associ w/short-term development of PsA. Study of 64 PsO +arthralgia pts. IUS PD synovi

Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep

AutoAbs & protein signatures evolve as pts go from Preclinical to established RA. Pts vs controls distinguished w/in

Daily purposeful walking assoc w/ lower risk of Knee OA (KOA). UK Biobank study of 89,969 persons, F/U 6.8 yrs - 2711 de

Phase 3 trial shows inebilizumab reduces flares in IgG4-related disease (10% vs 60% in placebo; HR 0.13, p<0.001) and

✅ T2T in #Lupus 👀 ⬇️⬇️ 📥 LINK https://t.co/F8w8qRZdsS #NosVemosEnPANLAR2025 https://t.co/JNx1wdwMb4

Do you get our email newsletter?